China approves 16 home grown Covid-19 vaccines for clinical trials

Topics Coronavirus | China

China has approved clinical trials for 16 indigenous COVID-19 vaccines, of which six are in the third stage, according to a state-run media report.

The latest vaccines for clinical trials are based on recombinant protein, adenovirus vector, nucleic acid and attenuated influenza-viruses technologies, state-run Xinhua news agency reported on Saturday, citing data from the National Medical Products Administration.

Six of the vaccines are in the third stage of the trials, which is one of the last phases, it said.

China has already given conditional approval to two inactivated COVID-19 vaccines made by state-owned developers -- Sinopharm and Sinovac Biotech.

The coronavirus has claimed 4,833 lives, along with 100,727 confirmed cases in China, according to the Johns Hopkins University.

As of February 9, China has given 40.52 million COVID-19 jabs to key groups, Xinhua reported, quoting a National Health Commission official.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel